Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis

Cell - United States
doi 10.1016/j.cell.2019.01.002
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Direct Targeting of Oncogenic RAS Mutants With a Tumor-Specific Cytosol-Penetrating Antibody Inhibits RAS Mutant–driven Tumor Growth

Science advances
Multidisciplinary
2020English

Oncogenic NRAS Signaling Differentially Regulates Survival and Proliferation in Melanoma

Nature Medicine
BiochemistryMedicineGeneticsMolecular Biology
2012English

Targeting Oncogenic Ras

Genes and Development
GeneticsDevelopmental Biology
2007English

Selective Targeting of KRAS Oncogenic Alleles by CRISPR/Cas9 Inhibits Proliferation of Cancer Cells

Scientific Reports
Multidisciplinary
2018English

Pharmacological Targeting of MYC-regulated IRE1/XBP1 Pathway Suppresses MYC-driven Breast Cancer

Journal of Clinical Investigation
Medicine
2018English

GAB2 Induces Tumor Angiogenesis in NRAS-driven Melanoma

Oncogene
Cancer ResearchGeneticsMolecular Biology
2012English

Therapeutic Targeting of Oncogenic Tyrosine Phosphatases

Cancer Research
Cancer ResearchOncology
2017English

Molecular Pathways: Targeting NRAS in Melanoma and Acute Myelogenous Leukemia

Clinical Cancer Research
Cancer ResearchOncology
2014English

Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants

Cells
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy